The APOE4 gene affects 25% of the population and drives 44% of all Alzheimer's cases, creating a $181 billion annual burden in the U.S. alone. With 1.1 billion carriers worldwide facing dramatically ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, ...

The stock options have a ten-year term and an exercise price of $2.38 per share, which is equal to the closing price of Vor Bio’s common stock on July 17, 2025. The stock options will vest over a four ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).

The Anosh Inc Foundation is a nonprofit organization based in Chicago, focused on enhancing lives through programs in ...

ALK ( ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EUR neffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Net Profit Achieved: Q2 2025 marked Hapbee’s first profitable quarter in company history, with net income of $17,988, compared to a net loss of $178,984 in Q1 2025 and a loss of $1.86 million in Q2 ...

Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement ...